HPV Associated Disorders Market Report

HPV Associated Disorders Market Analysis, Market Size, Product Analysis, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2026

  • Published Date: ---
  • Base Year for Estimate: ---
  • Report ID: GVR6098
  • Format: Electronic (PDF)
  • Historical Data: ---
  • Number of Pages: 0

The global human papillomavirus (HPV) associated disorders market is projected to exhibit moderate growth through the forecast period, driven by the emergence of biologics and rising incidence of HPV associated diseases. Proactive government initiatives and steady growth in consumer awareness are likely to promote higher growth in this market.

There are more than 100 strains of HPV, out of which 13 are high-risk or cancerous. High vs low risk HPV strains are determined by the activated gene - E6 or E7. HPV infections are the most prevalent sexually transmitted infections. Unprotected sex, multiple sex partners, and a compromised immune system are some key causative factors for HPV related diseases.

The market is segmented by indications. HPV causes a wide array of diseases, including cervical intraepithelial neoplasia (CIN), cervical cancer, anal intraepithelial neoplasia (AIN), anal cancer, and genital warts. Cervical cancer is one of the largest indications in this market, supported by strong commercial performances of Avastin and Keytruda.

The market is further segmented on the basis of therapy into prevention and treatment. Vaccines remain the mainstay of preventive strategy for HPV infections. The treatment landscape is gradually shifting towards a targeted therapeutic approach. On the basis of sales channel, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies.

Geographically, the market has been divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Some of the major players in the global HPV associated disorders market include Merck & Co., Inc.; GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd; Pfizer, Inc.; Allergan plc; AstraZeneca plc; Biocon Ltd.; and Eli Lilly and Company.

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified